Another active week across the industry saw FluidAI expanding through acquisition, while investors backed AI platforms, clinical software, and novel brain-treatment technologies. The momentum behind intelligent, workflow-enhancing tools continues to build. Details follow below.
FluidAI Medical announces an acquisition deal with Emmetros Limited
FluidAI announced an acquisition deal with SparxConnect developer Emmetros Limited, a leading company in the patient engagement space. The acquisition enhances Stream Inara, an AI-powered patient education and engagement platform within FluidAI’s product portfolio that extends care beyond the hospital.
This is the company’s second acquisition deal after Medsix. Strategic acquisitions remain a core part of its growth strategy, strengthening its position in existing markets and expanding its footprint with established products and technologies.
CEO Youssef Helwa
Last week’s tracker: Distalmotion, Okami & more
Arbiter raises $52m in seed funding
Arbiter raised $52 million in seed funding at a $400 million valuation. It raised the round from multiple family offices, which are essentially private investment firms that manage all aspects of a wealthy family’s finances.
TriEdge Investments and MFO Ventures co-led the round, joined by private equity firm WindRose Health Investors.
CEO Michelle Carnahan
Sorcero raises $42.5m to support global expansion
The Series B funding round will be used to expedite the company’s global growth in the medical device, medical affairs, safety and scientific communications sectors. NewSpring Growth spearheaded the funding round, which also saw participation from Leawood Venture Capital and Blu Ventures.
The funding will also support further development of its AI platform to facilitate a medical-insights-driven engagement model and help address the life sciences industry’s need to promote the adoption of new therapies.
Co-founder and CEO Dipanwita Das
Nanox announces $15m registered direct offering of common stock
Nanox announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares in a registered direct offering.
The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
CEO Erez Meltzer
Gosta Labs completes $8.7m oversubscribed seed round
Gosta Labs closed an oversubscribed $8.7m million seed round to scale its AI operating system for complex medical specialties. This follows a $1.9 million pre-seed round in 2024 and brings the company’s total funding to nearly $11.5 million.
The round was led by Voima Ventures, with participation from COR Group, Terveystalo, the Aho family, and both existing and new investors, including Reaktor and a group of notable angel investors.
Co-founder and CEO Lauri Sippola
Cordance Medical raises $8m seed for focused ultrasound used in brain treatment
Sonder Capital led the round, which included participation from existing and new investors. Shanda Grab Ventures, Angel Physician’s Fund, SmartGateVC and R42 participated in the round.
The Sontag Foundation Innovation Fund, a subsidiary of The Sontag Foundation, and the Brain Tumor Investment Fund, a venture subsidiary of the National Brain Tumor Society, also joined. It plans to use the funds to support a first-in-human trial of its focused ultrasound system.
Co-founder and CEO Bhaskar Ramamurthy
SymPhysis Medical wins $1.3m grant to advance cancer device in US
SymPhysis Medical won a $1.3m grant to advance the development of a cancer treatment device in the United States through the Rhode Island Life Science Hub.
This funding will support the US development of a unique drainage device, to treat malignant pleural effusion.
Co-founder and CEO Tim Jones
